Dr. Dan Weng is appointed as a Chief Executive Officer, Director of the company effect from 1 July 2017. He has extensive experience in managing and growing CRO businesses, including nearly six years at EPS International Holding Co. ("EPSI"), subsidiary of EPSHD, where he was Chairman, President and CEO. During his tenure at EPSI, Dr Weng oversaw significant growth, both organically and through M&A in Asia, the US and Europe, with revenues increasing over five-fold. Dr Weng's background covers multiple therapeutic areas, supporting all stages of development through to approval. He was also a Board Director of EPSHD and had an active role in corporate strategy and investor relations. Prior to this, Dr Weng has a proven track record with 20 years of delivering growth in executive positions at international CROs including MedPace, Icon Clinical Research, PharmaNet and Quintiles, where he established the offering in China. Dr Weng qualified as a medical doctor at Tongji Medical University, China, and holds an MA in Health Planning, Policy and Management from the University of Leeds, UK. He also held research positions at Harvard Medical School - Massachusetts General Hospital and the University of California.

Multiple therapeutic areas,Icon Clinical Research